Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK120 (Manfidokimab) in Moderate-to-Severe Asthma
NCT05155020Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of manfidokimab in asthma (4 arms), sponsored by Akeso, Inc. Primary endpoint: Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1) from baseline at 12 weeks. Started Feb 2022; status: terminated.
02
Drugs
manfidokimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05155020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155020.